MI Therapeutics Market to Grow by USD 2.02 billion | Rising Incidence of MI to Boost Growth | Technavio

Myocardial Infarction (MI) Therapeutics Market 2022-2026 : Scope

The myocardial infarction (mi) therapeutics market report covers the following areas:

• Myocardial Infarction (MI) Therapeutics Market size
• Myocardial Infarction (MI) Therapeutics Market trends
• Myocardial Infarction (MI) Therapeutics Market industry analysis

Myocardial Infarction (MI) Therapeutics Market 2022-2026 : Segmentation

By product, the market has been segmented into antithrombotics, vasodilators, thrombolytics, and others. The antithrombotics segment will have significant market share growth during the forecast period. The growth of this segment can be attributed to the increasing demand for NOACs worldwide.

By geography, the market has been segmented into North America, Asia, Europe, and Rest Of World (ROW). North America will account for the highest share during the forecast period.

Learn more about the contribution of each segment of the market. Download a Free Sample

Myocardial Infarction (MI) Therapeutics Market 2022-2026 : Drivers and Challenges

The rising incidence of MI is one of the key factors driving the global myocardial infarction (MI) therapeutics market growth. Novel antithrombotics offer significant advantages, such as target specificity. Furthermore, in developed nations, reimbursement programs aim at providing full-time coverage for drug therapies as well as cardiovascular imaging and acute care. These factors are contributing to the growth of the market in the forecast period.

The extensive use of generics is one of the key challenges to the global myocardial infarction (MI) therapeutics market growth. Generic drugs are allowed for sale after the expiry of the patent of the original branded drug. Thus, generic drugs have comparatively lower prices than branded drugs. In addition, the high success rates associated with implantable cardioverter defibrillators (ICDs) and vest prevention of early sudden death trial (VEST) have led to their increased adoption rate among end-users. These factors limit the use of MI therapeutics to a certain extent among patients, thereby restricting the market growth.

Myocardial Infarction (MI) Therapeutics Market 2022-2026 : Vendor Analysis

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments while maintaining their positions in the slow-growing segments.

We provide a detailed analysis of around 25 vendors operating in the myocardial infarction (MI) therapeutics market, including Amgen Inc., AstraZeneca Plc, Athera Biotechnologies AB, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CeleCor Therapeutics, CHIESI Farmaceutici SpA, CSL Ltd., Eli Lilly and Co., Ever Supreme Bio Technology, F. Hoffmann La Roche Ltd., Faraday Pharmaceuticals, Idorsia Pharmaceuticals Ltd., Merck and Co. Inc., Mesoblast Ltd., Novartis AG, Pfizer Inc., Sanofi SA, and Johnson and Johnson Inc. among others.

Subscribe to our "Lite Plan" billed annually at USD 3000 that enables to download 3 reports/year and view 3 reports/month.

Myocardial Infarction (MI) Therapeutics Market 2022-2026 : Key Highlights

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will assist myocardial infarction (MI) therapeutics market growth during the next five years
• Estimation of the myocardial infarction (MI) therapeutics market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the myocardial infarction (MI) therapeutics market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of myocardial infarction (MI) therapeutics market vendors

Related Reports:

New Drug Delivery Systems Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

Janus Kinase (JAK) Inhibitors Market by Application and Geography - Forecast and Analysis 2022-2026

Table Of Contents :

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Antithrombotics - Market size and forecast 2021-2026
• Exhibit 28: Chart on Antithrombotics - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Antithrombotics - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Antithrombotics - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Antithrombotics - Year-over-year growth 2021-2026 (%)

• 5.4 Vasodilators - Market size and forecast 2021-2026
• Exhibit 32: Chart on Vasodilators - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Vasodilators - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Vasodilators - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Vasodilators - Year-over-year growth 2021-2026 (%)

• 5.5 Thrombolytics - Market size and forecast 2021-2026
• Exhibit 36: Chart on Thrombolytics - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Thrombolytics - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Thrombolytics - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Thrombolytics - Year-over-year growth 2021-2026 (%)

• 5.6 Others - Market size and forecast 2021-2026
• Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Product
• Exhibit 44: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.5 Europe - Market size and forecast 2021-2026
• Exhibit 58: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 Mexico - Market size and forecast 2021-2026
• Exhibit 82: Chart on Mexico - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on Mexico - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on Mexico - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on Mexico - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 92: Matrix on vendor position and classification

• 10.3 Amgen Inc.
• Exhibit 93: Amgen Inc. - Overview
• Exhibit 94: Amgen Inc. - Product / Service
• Exhibit 95: Amgen Inc. - Key offerings

• 10.4 AstraZeneca Plc
• Exhibit 96: AstraZeneca Plc - Overview
• Exhibit 97: AstraZeneca Plc - Product / Service
• Exhibit 98: AstraZeneca Plc - Key news
• Exhibit 99: AstraZeneca Plc - Key offerings

• 10.5 Bayer AG
• Exhibit 100: Bayer AG - Overview
• Exhibit 101: Bayer AG - Business segments
• Exhibit 102: Bayer AG - Key news
• Exhibit 103: Bayer AG - Key offerings
• Exhibit 104: Bayer AG - Segment focus

• 10.6 Bristol Myers Squibb Co.
• Exhibit 105: Bristol Myers Squibb Co. - Overview
• Exhibit 106: Bristol Myers Squibb Co. - Product / Service
• Exhibit 107: Bristol Myers Squibb Co. - Key offerings

• 10.7 Eli Lilly and Co.
• Exhibit 108: Eli Lilly and Co. - Overview
• Exhibit 109: Eli Lilly and Co. - Business segments
• Exhibit 110: Eli Lilly and Co. - Key offerings
• Exhibit 111: Eli Lilly and Co. - Segment focus

• 10.8 F. Hoffmann La Roche Ltd.
• Exhibit 112: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 113: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 114: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 115: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 116: F. Hoffmann La Roche Ltd. - Segment focus

• 10.9 Merck and Co. Inc.
• Exhibit 117: Merck and Co. Inc. - Overview
• Exhibit 118: Merck and Co. Inc. - Business segments
• Exhibit 119: Merck and Co. Inc. - Key news
• Exhibit 120: Merck and Co. Inc. - Key offerings
• Exhibit 121: Merck and Co. Inc. - Segment focus

• 10.10 Novartis AG
• Exhibit 122: Novartis AG - Overview
• Exhibit 123: Novartis AG - Business segments
• Exhibit 124: Novartis AG - Key offerings
• Exhibit 125: Novartis AG - Segment focus

• 10.11 Pfizer Inc.
• Exhibit 126: Pfizer Inc. - Overview
• Exhibit 127: Pfizer Inc. - Product / Service
• Exhibit 128: Pfizer Inc. - Key news
• Exhibit 129: Pfizer Inc. - Key offerings

• 10.12 Sanofi SA
• Exhibit 130: Sanofi SA - Overview
• Exhibit 131: Sanofi SA - Business segments
• Exhibit 132: Sanofi SA - Key news
• Exhibit 133: Sanofi SA - Key offerings
• Exhibit 134: Sanofi SA - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 135: Inclusions checklist
• Exhibit 136: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 137: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 138: Research methodology
• Exhibit 139: Validation techniques employed for market sizing
• Exhibit 140: Information sources

• 11.5 List of abbreviations
• Exhibit 141: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio